ASAisya Ayu Shafira

Aisya Ayu Shafira

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Aisya Ayu Shafira has a total of 11 co-authors. Here are the top co-authors by number of shared publications:

  • Budi Susetyo Pikir

    Department of Cardiology and Vascular Medicine, Faculty of Medicine, Universitas Airlangga, Surabaya 60132, Indonesia

    1 shared publication
  • Faizal A. Anandita

    Department of Cardiology and Vascular Medicine, Faculty of Medical, Universitas Airlangga, Surabaya, Indonesia; Department of Cardiology and Vascular Medicine, Dr. Soetomo General Hospital, Surabaya, Indonesia

    1 shared publication
  • Firda Fitra Qolbina

    Department of Cardiology and Vascular Medicine, Faculty of Medicine, Universitas Airlangga, Surabaya, East Java, Indonesia

    1 shared publication
  • Hanestya O. Hermawan

    Department of Cardiology and Vascular Medicine, Faculty of Medicine, Universitas Airlangga - Dr. Soetomo General Academic Hospital, Surabaya, Indonesia

    1 shared publication
  • Hanestya Oky Hermawan

    Universitas Airlangga

    1 shared publication
  • I Gr. Suryawan

    Department of Cardiology and Vascular Medicine, Faculty of Medicine, Universitas Airlangga - Dr. Soetomo General Academic Hospital, Surabaya, Indonesia

    1 shared publication

Latest Publications

  • Open Access

    Unintended Consequence – Iatrogenic Acute Pericarditis Following Right Ventricular Perforation by Temporary Pacemaker Lead in Total Atrioventricular Block

    by Firda Fitra Qolbina, Budi Susetyo Pikir, Aisya Ayu Shafira, Wynne Widiarti, Ihsan Fachry Arba, Pandit Bagus Tri Saputra

    Acute pericarditis is an uncommon but clinically significant complication of cardiac instrumentation that requires prompt recognition. This report describes a 48-year-old male with total AV block (TAVB) who developed iatrogenic acute pericarditis due to right ventricular (RV) perforation caused by a temporary pacemaker (TPM) lead. Imaging showed a lead protrusion through the posterior RV apex. Surgical exploration showed a thin-walled RV perforation with 300 mL of serous pericardial effusion and fibrin deposition. Primary RV repair was performed with 6-0 polypropylene sutures, and the TPM lead was removed. Postoperatively, the patient developed pleuritic chest pain and a pericardial friction rub. Cardiac computed tomography showed anterior and anterolateral pericardial thickening with minimal effusion, consistent with acute pericarditis. Iatrogenic myocardial injury may activate inflammasome pathways, driving sterile pericardial inflammation. The treatment with ibuprofen and colchicine led to rapid symptom resolution, C-reactive protein reduction, and near-complete effusion regression in 1 week without recurrence. This case underscores the need for prompt diagnosis and management of acute pericarditis associated with TPM-related RV perforation.

  • Open Access

    Invasive Strategy of STEMI in Patients with TAVB, RBBB, and Dual High-Risk Profiles: Navigating the Challenges of Antithrombotic Therapy – A Case Report

    by Aisya Ayu Shafira, Hanestya Oky Hermawan

    Background: It is imperative to diagnose and treat acute coronary occlusion as soon as possible, especially in patients with complicated conduction anomalies. Although electrocardiography (ECG) is still the gold standard for diagnosis, it has drawbacks, particularly when conduction abnormalities such as bundle branch block are present. Case Summary: In this case study, a 60-year-old woman with cardiovascular risk factors and type 2 diabetes had an anteroseptal STEMI that was worsened by RBBB and total AV block. The patient's recovery was complicated by extensive gastrointestinal bleeding after a successful percutaneous coronary intervention (PCI) and the implantation of a stent in the left anterior descending artery. Conclusion: In addition to highlighting the difficulties of striking a balance between dual antiplatelet therapy (DAPT) and reperfusion strategies in a high bleeding risk setting, this also highlights the management of a high-risk STEMI patient with total atrioventricular (AV) block, right bundle branch block (RBBB), and severe gastrointestinal complications. -- Highlights: 1. This case illustrates the complex management of STEMI with total AV block and right bundle branch block, where urgent PCI and temporary pacing achieved rapid hemodynamic stabilization. 2. Post-PCI gastrointestinal bleeding under dual antiplatelet therapy highlights the need for individualized antithrombotic strategies and vigilant post-discharge monitoring in high-risk patients.

  • Open Access

    Effect of SARS-CoV-2 spike protein exposure on ACE2 and interleukin 6 productions in human adipocytes: An in-vitro study

    by Meity Ardiana, I Gr. Suryawan, Hanestya O. Hermawan, Primasitha M. Harsono, Aisya A. Shafira, Faizal A. Anandita

    Since adipocytes play a crucial role in pathogenesis of severe acute respiratory syndrome coronavirus 2 (SARS‑CoV‑2) infection due to their interaction with angiotensin-converting enzyme 2 (ACE2) and interleukin 6 (IL-6), obesity is associated with an increased risk of coronavirus disease 2019 (COVID-19) mortality. Discovery of ACE2 as a SARS-CoV-2 receptor raises a controversy about whether to use ACE inhibitors (ACEIs) could be an optional therapy to prevent cytokine storms. Studies assessing the expressions of ACE2 and IL-6 upon exposure to SARS‑CoV‑2 is therefore important as a basis for therapeutical trials in the future. The aim of this study was to determine the effect of SARS-CoV-2 spike protein exposure on the production of ACE2 and IL-6 in adipocyte cells. Adipocytes were collected from abdominal adipose tissues of healthy and obese 45-year-old male donor having neither a history of SARS‑CoV‑2 infection nor COVID-19 vaccination. After being stained using the oil red O protocol, the viable adipocytes were then exposed to S1 subunit of SARS-CoV-2 spike protein. The levels of ACE2 and IL-6 were then examined using the enzyme-linked immunosorbent assay (ELISA). The results showed significant increase of ACE2 (90.22 µg/mL) and IL-6 level (60.01 µg/mL) in human adipocytes upon exposure compared to unexposed control cells (ACE2 13.33 µg/mL; IL-6 21.33 µg/mL), both comparisons had p<0.001). This study provides insight into the basic mechanism of severe COVID-19 symptoms in obese patients and provides a basic information of the potential of ACE inhibitors as an optional therapy for COVID-19 patients with obesity.